Survival analysis & interim looks
Group sequential designs and DSMB-facing interim analyses built for OS/PFS endpoints, with statistical support that keeps pace with amendment-driven protocol changes.
Why oncology sponsors choose us
Built for the pace of dose-escalation and survival endpoints
Three ways an integrated Biometrics and Clinical Operations model changes how an oncology program runs.
Safety-forward operations
Close site coordination around dose-limiting toxicity windows and safety run-in cohorts, feeding data back to biostatistics without the lag that slows dose-escalation decisions.
RECIST & biomarker data flow
Imaging and biomarker data reconciled against clinical response calls so subgroup and stratified analyses hold up when a program moves from Phase I into pivotal design.
Common questions
Before you scope an oncology study
Running an oncology program?
Tell us your phase, endpoints, and tumor type — we'll map a Biometrics and Clinical Operations model built for the pace your protocol needs.